RWA Wealth Partners LLC Purchases 55,700 Shares of Johnson & Johnson (NYSE:JNJ)

RWA Wealth Partners LLC grew its position in Johnson & Johnson (NYSE:JNJ) by 18.0% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 365,556 shares of the company’s stock after purchasing an additional 55,700 shares during the period. Johnson & Johnson comprises about 0.7% of RWA Wealth Partners LLC’s portfolio, making the stock its 25th largest position. RWA Wealth Partners LLC’s holdings in Johnson & Johnson were worth $52,867,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. IFS Advisors LLC raised its stake in Johnson & Johnson by 138.9% during the 4th quarter. IFS Advisors LLC now owns 172 shares of the company’s stock worth $25,000 after buying an additional 100 shares during the period. WealthTrak Capital Management LLC bought a new position in shares of Johnson & Johnson during the 4th quarter valued at about $26,000. Mountain Hill Investment Partners Corp. acquired a new position in shares of Johnson & Johnson in the 4th quarter valued at approximately $29,000. Bay Harbor Wealth Management LLC bought a new stake in Johnson & Johnson during the 4th quarter worth approximately $32,000. Finally, Runnymede Capital Advisors Inc. acquired a new stake in Johnson & Johnson during the 4th quarter worth approximately $38,000. 69.55% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

JNJ has been the subject of several recent research reports. Leerink Partners reduced their price objective on Johnson & Johnson from $182.00 to $169.00 and set an “outperform” rating for the company in a research report on Thursday, January 23rd. Guggenheim reaffirmed a “neutral” rating on shares of Johnson & Johnson in a research note on Monday, March 10th. Wells Fargo & Company cut their price objective on shares of Johnson & Johnson from $166.00 to $152.00 and set an “equal weight” rating on the stock in a research report on Thursday, January 23rd. Bank of America raised their target price on shares of Johnson & Johnson from $159.00 to $171.00 and gave the company a “neutral” rating in a research report on Wednesday, March 5th. Finally, Citigroup cut their price target on shares of Johnson & Johnson from $185.00 to $175.00 and set a “buy” rating on the stock in a research report on Wednesday, December 11th. Nine research analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have given a strong buy rating to the company. According to MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $171.33.

Insider Activity

In other news, VP Robert J. Decker sold 6,999 shares of Johnson & Johnson stock in a transaction that occurred on Tuesday, February 25th. The shares were sold at an average price of $165.88, for a total value of $1,160,994.12. Following the completion of the sale, the vice president now directly owns 21,001 shares in the company, valued at approximately $3,483,645.88. The trade was a 25.00 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Timothy Schmid sold 403 shares of the stock in a transaction that occurred on Tuesday, February 18th. The stock was sold at an average price of $156.15, for a total value of $62,928.45. Following the sale, the executive vice president now directly owns 15,098 shares in the company, valued at $2,357,552.70. This represents a 2.60 % decrease in their position. The disclosure for this sale can be found here. 0.16% of the stock is currently owned by company insiders.

Johnson & Johnson Trading Up 0.3 %

Shares of Johnson & Johnson stock opened at $163.63 on Friday. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.11 and a quick ratio of 0.86. The business has a fifty day simple moving average of $158.68 and a two-hundred day simple moving average of $156.13. Johnson & Johnson has a 1 year low of $140.68 and a 1 year high of $169.99. The company has a market capitalization of $394.32 billion, a price-to-earnings ratio of 24.61, a P/E/G ratio of 2.56 and a beta of 0.47.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.99 by $0.05. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The company had revenue of $22.52 billion during the quarter, compared to analysts’ expectations of $22.44 billion. During the same quarter last year, the company posted $2.29 EPS. Johnson & Johnson’s quarterly revenue was up 5.3% compared to the same quarter last year. Research analysts forecast that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, March 4th. Shareholders of record on Tuesday, February 18th were given a dividend of $1.24 per share. This represents a $4.96 annualized dividend and a yield of 3.03%. The ex-dividend date was Tuesday, February 18th. Johnson & Johnson’s payout ratio is 74.59%.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.